Mark Harnett
Overview
Explore the profile of Mark Harnett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Francioni V, Tang V, Toloza E, Brown N, Harnett M, Harnett M
bioRxiv
. 2023 Nov;
PMID: 37961227
Vectorization of teaching signals is a key element of virtually all modern machine learning algorithms, including backpropagation, target propagation and reinforcement learning. Vectorization allows a scalable and computationally efficient solution...
2.
Lang F, Kwon D, Aarsland D, Boeve B, Tousi B, Harnett M, et al.
Alzheimers Dement (N Y)
. 2021 Jun;
7(1):e12171.
PMID: 34189249
Introduction: A phase 2b clinical trial, HEADWAY-DLB, was performed to assess treatment with intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB). Methods: HEADWAY-DLB was a...
3.
Lang F, Mo Y, Sabbagh M, Solomon P, Boada M, Jones R, et al.
Alzheimers Dement (N Y)
. 2021 Jun;
7(1):e12136.
PMID: 34095437
Introduction: A previous phase 2b study supported the use of the 5-HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia. A phase 3 study, MINDSET,...
4.
Lu L, Harnett M, Reines S
J Opioid Manag
. 2020 Sep;
16(4):297-306.
PMID: 32885838
Tramadol is a centrally acting dual-mechanism (opioid and monoamine reuptake inhibition) analgesic that has been noted to have a lower risk of abuse compared to conventional opioids such as morphine....
5.
Singla N, Pollak R, Gottlieb I, Leiman D, Minkowitz H, Zimmerman J, et al.
Pain Ther
. 2020 Jul;
9(2):545-562.
PMID: 32683644
Introduction: This study is part of the registrational program for intravenously administered (IV) tramadol in the USA and compared the analgesic benefit and tolerability of two doses of IV tramadol...
6.
Minkowitz H, Leiman D, Lu L, Reines S, Ryan M, Harnett M, et al.
J Pain Res
. 2020 Jun;
13:1155-1162.
PMID: 32547178
Purpose: There is a need to reduce exposure to Schedule II opioids in the United States (US) due to the ongoing opioid epidemic. Schedule II opioids have higher potential for...
7.
Reines S, Goldmann B, Harnett M, Lu L
Subst Abuse
. 2020 Jun;
14:1178221820930006.
PMID: 32547049
Objective: To analyze the rates of misuse - that is, use in any way not directed by a doctor - of products containing oral tramadol, a Schedule IV opioid, from...
8.
Minkowitz H, Salazar H, Leiman D, Solanki D, Lu L, Reines S, et al.
Drugs R D
. 2020 May;
20(3):225-236.
PMID: 32409981
Background And Objective: Oral tramadol, an atypical opioid approved in the United States (US) since 1995 and a Schedule IV controlled substance, has less abuse liability compared to Schedule II...
9.
Lang F, Korner P, Harnett M, Karunakara A, Tifft C
Mol Genet Metab
. 2020 Jan;
129(3):228-235.
PMID: 31937438
Introduction: Type 1 GM1 gangliosidosis is an ultra-rare, rapidly fatal lysosomal storage disorder, with life expectancy of <3 years of age. To date, only one prospective natural history study of...
10.
Lu L, Ryan M, Harnett M, Atiee G, Reines S
Clin Pharmacol Drug Dev
. 2019 Oct;
9(4):537-546.
PMID: 31610100
Tramadol is a dual-mechanism (opiate and monoamine reuptake inhibition) analgesic. Intravenous (IV) tramadol has been widely prescribed outside the United States. However, there have not been studies comparing the pharmacokinetics...